{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:16:25Z","timestamp":1789884985856,"version":"4.0.1"},"reference-count":35,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.3892\/or.2014.3284","type":"journal-article","created":{"date-parts":[[2014,6,23]],"date-time":"2014-06-23T12:43:39Z","timestamp":1403527419000},"page":"943-950","source":"Crossref","is-referenced-by-count":12,"title":["An ovarian cancer model with positive ER: Reversion of ER antagonist resistance by Src blockade"],"prefix":"10.3892","volume":"32","author":[{"given":"LONG","family":"LI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XIAOJUN","family":"LI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XIAOBING","family":"HAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TING","family":"YANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JING","family":"FU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YUNFENG","family":"ZHANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WENLI","family":"GOU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2014,6,23]]},"reference":[{"key":"key20180107205703_b1-or-32-03-0943","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"key20180107205703_b2-or-32-03-0943","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"key20180107205703_b3-or-32-03-0943","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.1158\/1078-0432.CCR-12-1257","article-title":"Src inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo","volume":"18","author":"Simpkins","year":"2012","journal-title":"Clin Cancer Res"},{"key":"key20180107205703_b4-or-32-03-0943","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ygyno.2013.07.099","article-title":"Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer","volume":"131","author":"Argenta","year":"2013","journal-title":"Gynecol Oncol"},{"key":"key20180107205703_b5-or-32-03-0943","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jsbmb.2012.05.006","article-title":"Long-term treatment with the pure anti-estrogen fulvestrant durably remodels estrogen signaling in BG-1 ovarian cancer cells","volume":"132","author":"Badia","year":"2012","journal-title":"J Steroid Biochem Mol Biol"},{"key":"key20180107205703_b6-or-32-03-0943","doi-asserted-by":"crossref","first-page":"e44787","DOI":"10.1371\/journal.pone.0044787","article-title":"Potential role of estrogen receptor beta as a tumor suppressor of epithelial ovarian cancer","volume":"7","author":"Bossard","year":"2012","journal-title":"PLoS One"},{"key":"key20180107205703_b7-or-32-03-0943","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s12253-010-9340-0","article-title":"Estrogen receptor alpha expression in ovarian cancer predicts longer overall survival","volume":"17","author":"Halon","year":"2011","journal-title":"Pathol Oncol Res"},{"key":"key20180107205703_b8-or-32-03-0943","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2298\/AOO1002032K","article-title":"Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: a case report and review of the literature","volume":"18","author":"Kothari","year":"2010","journal-title":"Arch Oncol"},{"key":"key20180107205703_b9-or-32-03-0943","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1158\/1078-0432.CCR-06-2878","article-title":"Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients","volume":"13","author":"Smyth","year":"2007","journal-title":"Clin Cancer Res"},{"key":"key20180107205703_b10-or-32-03-0943","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.tox.2012.12.021","article-title":"Benzophenone-1 stimulated the growth of BG-1 ovarian cancer cells by cell cycle regulation via an estrogen receptor alpha-mediated signaling pathway in cellular and xenograft mouse models","volume":"305","author":"Park","year":"2013","journal-title":"Toxicology"},{"key":"key20180107205703_b11-or-32-03-0943","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.3892\/mmr.2013.1650","article-title":"Euphol arrests breast cancer cells at the G1 phase through the modulation of cyclin D1, p21 and p27 expression","volume":"8","author":"Wang","year":"2013","journal-title":"Mol Med Rep"},{"key":"key20180107205703_b12-or-32-03-0943","article-title":"Gene delivery of cyclin-dependent kinase inhibitors p21Waf1 and p27Kip1 suppresses proliferation of MCF-7 breast cancer cells in vitro","author":"Jiang","year":"2013","journal-title":"Breast Cancer"},{"key":"key20180107205703_b13-or-32-03-0943","doi-asserted-by":"crossref","first-page":"8384","DOI":"10.1158\/1078-0432.CCR-05-1270","article-title":"Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer","volume":"11","author":"Psyrri","year":"2005","journal-title":"Clin Cancer Res"},{"key":"key20180107205703_b14-or-32-03-0943","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1006\/gyno.2001.6376","article-title":"Expression and subcellular localization of the cyclin-dependent kinase inhibitor p27Kip1 in epithelial ovarian cancer","volume":"83","author":"Hurteau","year":"2001","journal-title":"Gynecol Oncol"},{"key":"key20180107205703_b15-or-32-03-0943","doi-asserted-by":"crossref","first-page":"6936","DOI":"10.1073\/pnas.0502256102","article-title":"A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance","volume":"102","author":"Xing","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107205703_b16-or-32-03-0943","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"key":"key20180107205703_b17-or-32-03-0943","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11010-012-1550-1","article-title":"Expression of c-Src and phospho-Src in epithelial ovarian carcinoma","volume":"376","author":"Huang","year":"2013","journal-title":"Mol Cell Biochem"},{"key":"key20180107205703_b18-or-32-03-0943","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1158\/1078-0432.CCR-10-2081","article-title":"Functional roles of Src and Fgr in ovarian carcinoma","volume":"17","author":"Kim","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key20180107205703_b19-or-32-03-0943","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1158\/1078-0432.CCR-10-3176","article-title":"Targeting SRC in mucinous ovarian carcinoma","volume":"17","author":"Matsuo","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key20180107205703_b20-or-32-03-0943","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1159\/000338489","article-title":"EMT phenotype is induced by increased Src kinase activity via Src-mediated caspase-8 phosphorylation","volume":"29","author":"Zhao","year":"2012","journal-title":"Cell Physiol Biochem"},{"key":"key20180107205703_b21-or-32-03-0943","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.1038\/onc.2011.642","article-title":"Tyrosine phosphorylation of estradiol receptor by Src regulates its hormone-dependent nuclear export and cell cycle progression in breast cancer cells","volume":"31","author":"Castoria","year":"2012","journal-title":"Oncogene"},{"key":"key20180107205703_b22-or-32-03-0943","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2006.11.049","article-title":"p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2","volume":"128","author":"Chu","year":"2007","journal-title":"Cell"},{"key":"key20180107205703_b23-or-32-03-0943","first-page":"14","article-title":"The role of hormonal factors and endocrine therapy in ovarian cancer","volume":"17","author":"Serkies","year":"2013","journal-title":"Contemp Oncol"},{"key":"key20180107205703_b24-or-32-03-0943","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature11962","article-title":"Stem cells: anatomy of an ovarian cancer","volume":"495","author":"Brenton","year":"2013","journal-title":"Nature"},{"key":"key20180107205703_b25-or-32-03-0943","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","article-title":"Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1\u201398","volume":"25","author":"Coates","year":"2007","journal-title":"J Clin Oncol"},{"key":"key20180107205703_b26-or-32-03-0943","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S1470-2045(11)70270-4","article-title":"Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1\u201398 randomised clinical trial at 8.1 years median follow-up","volume":"12","author":"Regan","year":"2011","journal-title":"Lancet Oncol"},{"key":"key20180107205703_b27-or-32-03-0943","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1038\/onc.2010.604","article-title":"Translationally controlled tumor protein induces human breast epithelial cell transformation through the activation of Src","volume":"30","author":"Jung","year":"2011","journal-title":"Oncogene"},{"key":"key20180107205703_b28-or-32-03-0943","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/jcb.22219","article-title":"Src and FAK mediate cell-matrix adhesion-dependent activation of Met during transformation of breast epithelial cells","volume":"107","author":"Hui","year":"2009","journal-title":"J Cell Biochem"},{"key":"key20180107205703_b29-or-32-03-0943","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1158\/1535-7163.MCT-10-0019","article-title":"ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells","volume":"9","author":"Nautiyal","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"key20180107205703_b30-or-32-03-0943","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1158\/1535-7163.MCT-09-1117","article-title":"Development of candidate genomic markers to select breast cancer patients for dasatinib therapy","volume":"9","author":"Moulder","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"key20180107205703_b31-or-32-03-0943","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.clbc.2011.03.021","article-title":"Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer","volume":"11","author":"Gucalp","year":"2011","journal-title":"Clin Breast Cancer"},{"key":"key20180107205703_b32-or-32-03-0943","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1158\/1078-0432.CCR-10-0066","article-title":"Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer","volume":"16","author":"Arcaroli","year":"2010","journal-title":"Clin Cancer Res"},{"key":"key20180107205703_b33-or-32-03-0943","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/ncb2788","article-title":"Emerging regulation and functions of autophagy","volume":"15","author":"Boya","year":"2013","journal-title":"Nat Cell Biol"},{"key":"key20180107205703_b34-or-32-03-0943","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1056\/NEJMra1205406","article-title":"Autophagy in human health and disease","volume":"368","author":"Choi","year":"2013","journal-title":"N Engl J Med"},{"key":"key20180107205703_b35-or-32-03-0943","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1038\/onc.2012.455","article-title":"Ambra1 at the crossroad between autophagy and cell death","volume":"32","author":"Fimia","year":"2013","journal-title":"Oncogene"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2014.3284\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T20:57:15Z","timestamp":1515358635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2014.3284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,23]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,6,23]]},"published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.3892\/or.2014.3284"],"URL":"https:\/\/doi.org\/10.3892\/or.2014.3284","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,23]]}}}